KALA BIO Form 3 shows CEO and director hold no KALA stock

Rhea-AI Filing Summary

KALA BIO, Inc. (KALA) disclosed an initial ownership report for its Chief Executive Officer and director, David E. Lazar. This Form 3 shows that he beneficially owns no shares of KALA common stock as of the reported event date of 11/24/2025. The filing also indicates there are no derivative securities, such as options or warrants, reported as beneficially owned. This is an administrative disclosure required for insiders when they first become subject to reporting rules.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lazar David E.

Role Chief Executive Officer

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 0 shares (Direct)

Footnotes (1)

1. [object Object]

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lazar David E.

(Last) (First) (Middle)

44, TOWER 100, THE TOWERS

WINSTON CHURCHILL, PAITILLA

(Street)

PANAMA CITY R1 07196

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
11/24/2025

3. Issuer Name and Ticker or Trading Symbol
KALA BIO, Inc. [ KALA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	0(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. No shares of common stock are beneficially owned.

	/s/ David E. Lazar	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the KALA BIO (KALA) Form 3 filed by David E. Lazar report?

The Form 3 reports that David E. Lazar, KALA BIO's Chief Executive Officer and director, currently beneficially owns 0 shares of common stock and no derivative securities.

How many KALA BIO (KALA) common shares does the CEO beneficially own?

The filing states that the CEO, David E. Lazar, beneficially owns 0 shares of KALA BIO common stock, as noted in the explanation of responses.

Are any options or other derivative securities reported for KALA BIO’s CEO?

No. The Table II section for derivative securities is empty, indicating no derivative securities are beneficially owned by the reporting person.

What is David E. Lazar’s role at KALA BIO (KALA) according to the filing?

The report identifies David E. Lazar as both a Director and an Officer, with the title of Chief Executive Officer of KALA BIO, Inc.

Is this KALA BIO (KALA) Form 3 filed by more than one reporting person?

No. The form indicates it is filed by one reporting person, specifically David E. Lazar, and is not a joint or group filing.

What explanation is given for the zero share ownership in the KALA BIO Form 3?

The explanation of responses states: “No shares of common stock are beneficially owned.” This clarifies that the reporting person currently has no beneficial ownership.